Kurt L. Pflieger, M.D.; Order Dismissing Order To Show Cause, 2577-2578 [2019-01528]
Download as PDF
<![CDATA[
2577
Federal Register / Vol. 84, No. 26 / Thursday, February 7, 2019 / Notices
Registrants listed below have
applied for and been granted
registration by-the Drug Enforcement
Administration (DEA) as importers of
various classes of schedule I or II
controlled substances.
SUMMARY:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration
ACTION:
classes of controlled substances.
Information on previously published
notices is listed in the table below. No
comments or objections were submitted
and no requests for hearing were
submitted for these notices.
The
companies listed below applied to be
registered as importers of various basic
SUPPLEMENTARY INFORMATION:
Notice of registration.
Company
FR docket
Noramco Inc ......................................................................................................................................................
Catalent CTS, LLC ............................................................................................................................................
United States Pharmacopeial Convention ........................................................................................................
Fisher Clinical Services, Inc .............................................................................................................................
Cambrex High Point, Inc ...................................................................................................................................
Sharp (Bethlehem), LLC ...................................................................................................................................
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of the
listed registrants to import the
applicable basic classes of schedule I or
II controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated each company’s
maintenance of effective controls
against diversion by inspecting and
testing each of the company’s physical
security systems, verifying each
company’s compliance with state and
local laws, and reviewing each
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the DEA has
granted a registration as an importer for
schedule I or II controlled substances to
the above listed companies.
Dated: December 21, 2018.
John J. Martin,
Assistant Administrator.
83
83
83
83
83
83
FR
FR
FR
FR
FR
FR
53107
54613
54611
54612
54610
54612
The
companies listed below applied to be
registered as bulk manufacturers of
various basic classes of controlled
substances. Information on previously
published notices is listed in the table
below. No comments or objections were
submitted for these notices.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Registration
ACTION:
Notice of registration.
83 FR 48334
83 FR 49578
Jkt 247001
2018.
2018.
2018.
2018.
2018.
2018.
SUPPLEMENTARY INFORMATION:
[FR Doc. 2019–01519 Filed 2–6–19; 8:45 am]
AMPAC Fine Chemicals Virginia, LLC ..........................................................................................................
AMPAC Fine Chemicals, LLC .......................................................................................................................
17:23 Feb 06, 2019
19,
30,
30,
30,
30,
30,
The registrants listed below
has applied for and has been granted
registration by the Drug Enforcement
Administration (DEA) as bulk
manufacturer of various classes of
schedule I and II controlled substances.
FR Docket
VerDate Sep<11>2014
October
October
October
October
October
October
SUMMARY:
Company
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of this registrant to
manufacture the applicable basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing their physical
security systems, verifying their
compliance with state and local laws,
and reviewing each of the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the DEA has granted a
Published
registration as a bulk manufacturer to
the above listed companies.
Dated: December 21, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–01525 Filed 2–6–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 2018–43]
Kurt L. Pflieger, M.D.; Order
Dismissing Order To Show Cause
On July 12, 2018, the Assistant
Administrator, Diversion Control
Division, Drug Enforcement
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
Published
September 24, 2018.
October 2, 2018.
Administration (hereinafter, DEA or
Government), issued an Order to Show
Cause to Kurt L. Pflieger, M.D.
(hereinafter, Respondent), of Rockwall,
Texas. Order to Show Cause
(hereinafter, OSC), at 1. The OSC
proposes the revocation of Respondent’s
Certificate of Registration on the ground
that he does not have authority to
handle controlled substances in the
State of Texas, the State in which he is
registered with the DEA. Id.
After the Administrative Law Judge
(hereinafter, ALJ) certified and
transmitted the record to me along with
his Recommended Decision, the
Government submitted a ‘‘Motion to
Dismiss Order to Show Cause’’
(hereinafter, Motion). According to the
Motion, the Texas Medical Board held
E:\FR\FM\07FEN1.SGM
07FEN1
2578
Federal Register / Vol. 84, No. 26 / Thursday, February 7, 2019 / Notices
a hearing after the ALJ granted the
Government’s Motion for Summary
Disposition and recommended
revocation of Respondent’s registration.
Motion, at 1. The Motion also states
that, as a result of the hearing, the Texas
Medical Board suspended Respondent’s
medical license, ordered that the
suspension be stayed, and placed
Respondent on five years’ probation
under various terms and conditions. Id.
The Motion concludes by stating that,
‘‘Since . . . [Respondent] now has state
authority to handle controlled
substances, the DEA respectfully
request[s] the Administrator to dismiss
the pending Order to Show Cause and
recommended ruling from the
Administrative Law Judge.’’ Id. at 2.
Accordingly, I shall dismiss the Order to
Show Cause.
Order
Pursuant to 28 CFR 0.100(b) and the
authority thus vested in me by 21 U.S.C.
823(f) and 824(a), I order that the Order
to Show Cause issued to Kurt L.
Pflieger, M.D. be, and it hereby is,
dismissed. This Order is effective March
11, 2019.
Dated: January 17, 2019.
Uttam Dhillon,
Acting Administrator.
[FR Doc. 2019–01528 Filed 2–6–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Chattem Chemicals
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before March 11, 2019. Such persons
may also file a written request for a
hearing on the application on or before
March 11, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
DATES:
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on October
31, 2018, Chattem Chemicals Inc., 3801
Saint Elmo Avenue, Chattanooga,
Tennessee 37409–1237 applied to be
registered as an importer of the
following basic classes of controlled
substances:
SUPPLEMENTARY INFORMATION:
Drug
code
Controlled substance
Methamphetamine ...................................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .............................................................................................................................
Phenylacetone .........................................................................................................................................................................
Opium, raw ..............................................................................................................................................................................
Poppy Straw Concentrate .......................................................................................................................................................
Tapentadol ...............................................................................................................................................................................
The company plans to import the
listed controlled substances to
manufacture bulk controlled substances
for sale to its customers.
The company plans to import an
intermediate of tapentadol (9780), to
bulk manufacture tapentadol for
distribution to its customers.
DEPARTMENT OF JUSTICE
Dated: December 21, 2018.
John J. Martin,
Assistant Administrator.
ACTION:
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Registration
Notice of registration.
Registrants listed below have
applied for and been granted a
registration by the Drug Enforcement
Administration (DEA) as bulk
SUMMARY:
[FR Doc. 2019–01512 Filed 2–6–19; 8:45 am]
BILLING CODE 4410–09–P
The
companies listed below applied to be
registered as bulk manufacturers of
various basic classes of controlled
substances. Information on previously
published notices are listed in the table
below. No comments or objections were
submitted for these notices.
SUPPLEMENTARY INFORMATION:
FR
Docket
National Center for Natural Products Research NIDA MPROJECT ............................................................
Halo Pharmaceutical, Inc ..............................................................................................................................
Nanosyn, Inc .................................................................................................................................................
83 FR 48334
83 FR 48334
83 FR 48867
17:23 Feb 06, 2019
Jkt 247001
PO 00000
Frm 00092
Fmt 4703
Sfmt 4703
II
II
II
II
II
II
manufacturers of various classes of
schedule I and II controlled substances.
Company
VerDate Sep<11>2014
1105
8333
8501
9600
9670
9780
Schedule
E:\FR\FM\07FEN1.SGM
07FEN1
Published
August 31, 2018.
September 24, 2018.
September 27, 2018.
]]>Agencies
[Federal Register Volume 84, Number 26 (Thursday, February 7, 2019)]
[Notices]
[Pages 2577-2578]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-01528]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 2018-43]
Kurt L. Pflieger, M.D.; Order Dismissing Order To Show Cause
On July 12, 2018, the Assistant Administrator, Diversion Control
Division, Drug Enforcement Administration (hereinafter, DEA or
Government), issued an Order to Show Cause to Kurt L. Pflieger, M.D.
(hereinafter, Respondent), of Rockwall, Texas. Order to Show Cause
(hereinafter, OSC), at 1. The OSC proposes the revocation of
Respondent's Certificate of Registration on the ground that he does not
have authority to handle controlled substances in the State of Texas,
the State in which he is registered with the DEA. Id.
After the Administrative Law Judge (hereinafter, ALJ) certified and
transmitted the record to me along with his Recommended Decision, the
Government submitted a ``Motion to Dismiss Order to Show Cause''
(hereinafter, Motion). According to the Motion, the Texas Medical Board
held
[[Page 2578]]
a hearing after the ALJ granted the Government's Motion for Summary
Disposition and recommended revocation of Respondent's registration.
Motion, at 1. The Motion also states that, as a result of the hearing,
the Texas Medical Board suspended Respondent's medical license, ordered
that the suspension be stayed, and placed Respondent on five years'
probation under various terms and conditions. Id.
The Motion concludes by stating that, ``Since . . . [Respondent]
now has state authority to handle controlled substances, the DEA
respectfully request[s] the Administrator to dismiss the pending Order
to Show Cause and recommended ruling from the Administrative Law
Judge.'' Id. at 2. Accordingly, I shall dismiss the Order to Show
Cause.
Order
Pursuant to 28 CFR 0.100(b) and the authority thus vested in me by
21 U.S.C. 823(f) and 824(a), I order that the Order to Show Cause
issued to Kurt L. Pflieger, M.D. be, and it hereby is, dismissed. This
Order is effective March 11, 2019.
Dated: January 17, 2019.
Uttam Dhillon,
Acting Administrator.
[FR Doc. 2019-01528 Filed 2-6-19; 8:45 am]
BILLING CODE 4410-09-P
